Edwards Lifesciences is to work with Bay Labs on improving the detection of heart disease. The partnership involves multiple initiatives, including the development of new AI-powered algorithms in Bay Labs’ EchoMD measurement and interpretation software suite, the integration of EchoMD algorithms into Edwards Lifesciences’ CardioCare quality care navigation platform, and support for ongoing clinical studies at leading institutions.
Multiple EchoMD algorithms have been integrated into the CardioCare platform for investigational use to retrospectively analyse echocardiograms. A press release reports that the companies believe that incorporating these and future algorithms into clinical practice could help drive quality improvement and potentially increase accurate heart disease detection.
The CardioCare program combines clinical consulting expertise with a cloud based platform to facilitate in the identification, referral, and care pathway management of patients with structural heart disease. CardioCare can help hospitals improve quality by reducing variability in echocardiography and ensure effective communication between care settings to ensure patients access to care. The EchoMD software suite assists cardiologists in automated review of images captured during echocardiograms.
Madalina Petrescu (Swedish Hospital, Seattle, USA), comments: “Improving detection of disease starts with better quality echoes. CardioCare helps to reduce variability in echoes, and I believe Bay Labs’ AI technology has the potential to impact patient lives, namely by improving the accuracy of disease detection and diagnosis.”
Charles Cadieu, co-founder and CEO of Bay Labs, states: “Our vision is to improve patient care throughout the continuum from disease detection to appropriate intervention. Working with Edwards to deploy Bay Labs’ AI software with deep learning technology into clinical settings has the potential to derive quality improvements and to increase the accuracy of timely heart disease detection.”
